You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

List of Excipients in API OXYMETAZOLINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing OXYMETAZOLINE HYDROCHLORIDE

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Allergan Inc RHOFADE oxymetazoline hydrochloride 0023-5300 ANHYDROUS CITRIC ACID
Allergan Inc RHOFADE oxymetazoline hydrochloride 0023-5300 BUTYLATED HYDROXYTOLUENE
Allergan Inc RHOFADE oxymetazoline hydrochloride 0023-5300 CETEARETH-25
Allergan Inc RHOFADE oxymetazoline hydrochloride 0023-5300 CETEARETH-6
Allergan Inc RHOFADE oxymetazoline hydrochloride 0023-5300 CETOSTEARYL ALCOHOL
Allergan Inc RHOFADE oxymetazoline hydrochloride 0023-5300 DIISOPROPYL ADIPATE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Get Started Free

Excipients in ANDA-approved (generic) drugs containing OXYMETAZOLINE HYDROCHLORIDE

Company Ingredient NDC Excipient
Taro Pharmaceuticals USA Inc oxymetazoline hydrochloride 51672-1405 ANHYDROUS CITRIC ACID
Taro Pharmaceuticals USA Inc oxymetazoline hydrochloride 51672-1405 BUTYLATED HYDROXYTOLUENE
Taro Pharmaceuticals USA Inc oxymetazoline hydrochloride 51672-1405 CETEARETH-25
Taro Pharmaceuticals USA Inc oxymetazoline hydrochloride 51672-1405 CETEARETH-6
Taro Pharmaceuticals USA Inc oxymetazoline hydrochloride 51672-1405 CETOSTEARYL ALCOHOL
Taro Pharmaceuticals USA Inc oxymetazoline hydrochloride 51672-1405 DIISOPROPYL ADIPATE
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for OXYMETAZOLINE HYDROCHLORIDE

Excipient focus: ANHYDROUS CITRIC ACID

Excipient focus: BUTYLATED HYDROXYTOLUENE

Excipient focus: CALCIUM CHLORIDE

Excipient focus: CETEARETH-25

Excipient focus: CETEARETH-6

Excipient focus: CETOSTEARYL ALCOHOL

Excipient focus: DIISOPROPYL ADIPATE

Excipient focus: EDETATE DISODIUM

Excipient focus: GLYCOL STEARATE

Excipient focus: HYDROCHLORIC ACID

Excipient focus: HYPROMELLOSE

Excipient focus: LANOLIN

Excipient focus: MAGNESIUM CHLORIDE

Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES

Excipient focus: METHYLPARABEN

Excipient focus: OLEYL ALCOHOL

Excipient focus: PEG-32 STEARATE

Excipient focus: PEG-6 STEARATE

Excipient focus: PHENOXYETHANOL

Excipient focus: POLYETHYLENE GLYCOL 300

Excipient focus: POLYSORBATE 60

Excipient focus: POTASSIUM CHLORIDE

Excipient focus: PROPYLPARABEN

Excipient focus: SODIUM ACETATE

Excipient focus: SODIUM CHLORIDE

Excipient focus: SODIUM CITRATE

Excipient focus: SORBITAN MONOSTEARATE

Excipient focus: STEARYL ALCOHOL

Excipient focus: TRISODIUM CITRATE DIHYDRATE

Excipient focus: WATER

OXYMETAZOLINE HYDROCHLORIDE drug variants containing WATER

Company Ingredient NDC
Allergan Inc oxymetazoline hydrochloride 0023-5300
Taro Pharmaceuticals USA Inc oxymetazoline hydrochloride 51672-1405
Mayne Pharma oxymetazoline hydrochloride 51862-765
Aclaris Therapeutics Inc oxymetazoline hydrochloride 71180-003
EPI Health LLC oxymetazoline hydrochloride 71403-003
RVL Pharmaceuticals Inc oxymetazoline hydrochloride ophthalmic 73687-062
>Company >Ingredient >NDC

Subscribe to access the full database, or Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links